Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Sinovac-QIV in Individuals Aged 3 Years and Older
NCT05431725Phase 3Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Jul 2022
- Primary completion
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of TetrAnflu in seasonal influenza (2 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Seroconversion rates of HI antibody and Geometric Mean Titers of HI antibody. Started Jul 2022; status: completed.
02
Drugs
TetrAnflu
03
Conditions
seasonal influenza
Beyond the preview
Go deeper on NCT05431725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05431725.